Ocean Genomics and Geninus Team Up to Develop RNA-Based Biomarkers and Advance Research.

Ocean Genomics, Geninus Inc | March 30, 2021

Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers.

The two organizations will dispatch in Korea Ocean Genomics' high level AI-based transcriptome analysis and biomarker stage (txome.ai) as both a cloud-put together and with respect to premises arrangement. Geninus will use the txome.ai stage to extend its CancerSCAN clinical diagnostics stage for its clinic clients, and for biomarker revelation administrations with scholastic and biotechnology customers. Ocean Genomics and Geninus will likewise accomplice on the co-development of a progression of RNA-educated multidimensional biomarkers for research and clinical use.

“We are excited to embark on this partnership with Geninus” said Carl Kingsford, co-founder and CEO, Ocean Genomics. “Ocean Genomics’ expertise in AI and computational method development, together with Geninus’ translational experts and access to data is a powerful combination. Working together, we can advance the field and enhance the uses of RNA biomarkers in clinical and research applications – and provide essential insights for clinicians who care for cancer patients.”

Dr. Woong Yang Park, CEO, Geninus, said, “Genome analysis for precision cancer medicine is becoming an essential process in hospitals. Gene expression analysis on tumor tissue RNA can deliver critical information for targeted therapy and immunotherapy. We expect to advance precision medicine by incorporating Ocean Genomics’ txome.ai into Geninus’ clinical diagnostics platform, CancerSCAN. We look forward to working with Ocean Genomics in co-developing biomarkers and expanding services to our academic and biotechnology customers.”

About Ocean Genomics, Inc.
Ocean Genomics’ mission is to enable drug development and personalized medicine by combining AI with advanced gene-expression analysis to determine rich gene expression signatures and develop RNA-informed multidimensional biomarkers. DNA is a predictor of what might happen in the future, while RNA reveals what’s happening now, making it an essential component in drug development, screening and monitoring, diagnosis and treatment selection. Analyzing RNA requires far more advanced software and computational methods than analyzing DNA.
Ocean Genomics provides the required specialized expertise in AI and transcriptomic analysis and advanced computational software solutions required to power discovery and development programs with life sciences companies and academic researchers. Ocean Genomics provides a self-service, fully configured, cloud-based platform, txome.ai, which provides advanced transcriptome analysis and biomarker generation.

About Geninus Inc.
Geninus provides clinical genome analysis solutions for precision medicine clinics. CancerSCAN, a cancer genome diagnostics platform, is used to inform personalized cancer treatment with targeted therapeutics and immunotherapy in major hospitals in Korea and Japan. CancerSCAN includes an information management system, a bioinformatics pipeline, variant annotation, clinical reports, and datacenter. OncoSTATION, a user interface for CancerSCAN, can be installed within hospital information systems. In addition, Geninus operates a single cell genome analysis platform called Celinus for biomarker discovery. Through collaborations with clinicians and pharmaceutical companies, Celinus can unearth new druggable targets or diagnostic markers in tumor microenvironment cells.


No doubt you have heard of dark matter, which is thought to make up over a quarter of the universe. We know it’s there; we just haven’t been able to detect it. Well, something similar is afoot in the genome. My colleagues and I have dubbed this elusive genetic matter “dark DNA”. And our investigations into the sand rat are starting to reveal its nature.


No doubt you have heard of dark matter, which is thought to make up over a quarter of the universe. We know it’s there; we just haven’t been able to detect it. Well, something similar is afoot in the genome. My colleagues and I have dubbed this elusive genetic matter “dark DNA”. And our investigations into the sand rat are starting to reveal its nature.

Related News


Merck Enters into Supply Agreement with U.S. Government to Manufacture and Initial Distribution of Investigational Biological Therapeutic

Merck | December 28, 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceutical organization. “Building upon the promising clinical findings to date for MK-7110, Merck is pleased to be collaborating with the U.S. Government to advance the manufacture and distribution of this candidate for patients with serious COVID-19 disease,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. Under the arrangement, Merck will get up to around $356 million for assembling and supply of roughly 60,000-100,000 dosages of MK-7110 to the U.S. Government through June 30, 2021 to meet the public authority's Operation Warp Speed objectives. This methodology is proposed to assist conveyance of MK-7110 to the American individuals as fast as could be expected under the circumstances, following potential EUA or FDA endorsement. Merck is manufacturing contributing to extend its assembling ability to expand supply of MK-7110.

Read More


Synthace Unveils First Life Sciences R&D Cloud Addressing Complexity, Speed & Reproducibility for Scientists

Synthace | August 03, 2021

Synthace, a leading life sciences software company, today announced the first life sciences R&D cloud that includes a no-code software platform addressing the largest barriers to innovation that R&D life scientists currently face. With the release of this new platform, Synthace is also the first vendor to enable scientists to automate experimentation and insight sharing in a unified, global R&D environment. Scientists can now focus on asking the most impactful questions and unlock the true potential of biology. To solve humanity’s hardest problems, such as delivering breakthrough therapies or alternative food sources, the life sciences industry is under tremendous pressure to simultaneously overcome biology’s complexity, accelerate speed to scientific insight, and ensure the reproducibility of experiments. Synthace alleviates these challenges by empowering scientists to improve and accelerate decision-making with more statistically powerful, automated experiments that can minimize human error. Furthermore, Synthace’s cloud platform leverages intelligent, dynamic automation to produce the highest quality data sets that are primed for machine learning (ML) and other advanced analyses to lead to better insights. With Synthace, the life sciences can now benefit from a quantum leap in experimentation capabilities, accelerating development timelines that would have previously been impossible. Customers Accelerate R&D with Synthace Ipsen has been using Synthace to automate the design and construction of therapeutic candidates. With Synthace, Ipsen produced approximately 90 constructs five times faster than previous methods, substantially increasing the number of molecules entering the screening cascade. The platform also achieved a 10-fold reduction in costs associated with DNA synthesis. Karen Bunting, Director of Protein Sciences at Ipsen commented, “Synthace sits very well at the beginning of our drug discovery process. It allows us to explore larger drug design space by simplifying planning and production of multiple molecule variants with combinatorial construct assembly. These throughput improvements help us deliver well-tolerated and effective therapeutic solutions more rapidly to our patients.” Microsoft Research also uses Synthace to automatically generate biological data at a volume that allows its ML algorithms to rapidly improve. As part of reporting on advancements in programming biological systems, a member of its Biocomputation Group noted: “Synthace really comes into its own when we’re performing experiments with complex layouts like combinatorial construct assembly and design of experiments. When we’re building 12 constructs at a time, Synthace automates all the planning that would go into setting up such an experiment and allows it to become routine.” Synthace Life Sciences R&D Cloud The platform provides end-to-end management of the experimental lifecycle, from design through execution to data visualization and knowledge transfer. Synthace adheres to FAIR principles to support interoperability with other major lab informatics platforms to ensure streamlined data management for all of its customers. Only the Synthace Life Sciences R&D Cloud delivers: Complete experimental design, planning and automation, requiring no coding expertise. Scientists can define more informative and impactful experiments that would otherwise be impossible to run and easily implement Quality by Design (QbD) and Design of Experiments (DOE). Seamless, cloud-based data capture, processing, and visualization. R&D teams can deliver deeper and faster insights from fully contextualized, machine learning-ready data sets that are automatically generated from the laboratory. Minimal deployment and onboarding. Customers experience rapid time-to-insight through Synthace’s out-of-the-box platform features and pre-validated protocols for common applications such as ELISA and high-throughput purification, helping them shorten R&D cycles and study more candidates per program. About Synthace Synthace is a life sciences software company enabling life science the way it should be done. Delivering a life sciences R&D cloud to scientists who want to innovate faster, the Synthace platform seamlessly automates experimentation and insight sharing so that scientists can focus on asking the most impactful questions to unlock the true potential of biology. Top global pharmaceuticals, high-growth biotech companies, leading CDMOs, and innovators in artificial intelligence all turn to Synthace to discover solutions to humanity’s hardest problems.

Read More


Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients

Leap Therapeutics, Inc. | February 01, 2022

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth. Overexpression of DKK1 is associated with poor survival in cancer patients. Leap Therapeutics is currently advancing the development of DKN-01, a humanized monoclonal antibody that targets DKK1, to treat cancer. The company is currently studying the drug as part of a combination therapy regimen in a Phase 2 clinical trial in patients with gastric or gastroesophageal junction cancer. The assay developed by Leica Biosystems will utilize RNAscope™ technology from Bio-Techne on the BOND-III Automated Staining System, which allows for detection of DKK1 with high sensitivity and specificity, to help identify patients most likely to benefit from DKN-01 treatment. "Companion Diagnostics are a step toward treating cancer patients based on the biomarker makeup of their disease.We are excited to partner with Leap to advance cancer care." Rachel Skelton, Senior Director of Pharma Partnerships at Leica Biosystems Companion Diagnostics are tests that may be used to determine if a patient's tumor has the biomarker that will predict the outcome of a treatment with a specific therapy. With expertise in assay development, regulatory approval and commercialization, the Leica Biosystems Companion Diagnostics team partners with pharmaceutical companies to develop assays for a diverse range of technologies. Our flexible approach to partnerships, along with the robust capabilities of the BOND Advance Staining Solutions, supports our mission of Advancing Cancer Diagnostics, Improving Lives. "DKK1 is novel and broadly applicable biomarker that is often elevated in patients with poor outcomes," said Jason Baum, Vice President and Head of Translational Medicine at Leap Therapeutics. "Patients whose tumors express elevated levels of DKK1 have shown compelling clinical responses when treated with DKN-01-based regimens. We are pleased to partner with Leica to advance the clinical development of our therapy and improve patient lives." About Leica Biosystems Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of corporate culture. Visit LeicaBiosystems.com for more information. About Leap Therapeutics Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 protein. DKN-01 is in clinical trials in patients with esophagogastric, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. About Bio-Techne Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnosis. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide.

Read More